26191
document
Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery . A placebo controlled study . In a double-blind , randomised study of thromboprophylaxis in patients undergoing total hip replacement , we compared a low-molecular-weight heparin with a placebo . Of the 120 patients enrolled , 112 completed the trial ; 58 in the treatment group and 54 in the placebo group . Nine ( 16 % ) patients in the treatment group and 19 ( 35 % ) in the placebo group developed deep venous thrombosis , diagnosed by the 125I-fibrinogen uptake test ( p < 0.02 ) . Verification was obtained by phlebography in 86 % of the patients . Prolonged surgery increased the risk of thrombosis in the placebo group but not in the treatment group ( p < 0.05 ) . There were significantly more cases of deep venous thrombosis in the placebo group during the first four postoperative days ( p < 0.02 ) . The groups did not differ with respect to peroperative and postoperative bleeding . Low-molecular-weight heparin offers safe and easily administered thromboprophylaxis in total hip replacement .
26192
Intervention_Pharmacological
low-molecular-weight heparin
26193
Intervention_Control
placebo
26194
Intervention_Pharmacological
low-molecular-weight heparin
26195
Intervention_Control
placebo
26196
Intervention_Control
placebo
26197
Intervention_Pharmacological
Low-molecular-weight heparin
26198
Outcome_Physical
deep venous thrombosis
26199
Outcome_Physical
risk of thrombosis
26200
Outcome_Physical
cases of deep venous thrombosis
26201
Outcome_Physical
peroperative and postoperative bleeding
26202
Participant_Condition
elective hip surgery
26203
Participant_Condition
total hip replacement